Navigation Links
Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
Date:5/20/2008

the global development and successful registration of several well-established cancer therapeutics. At Novartis, she served for close to 8 years in positions of increasing responsibility, including Executive Director, Oncology, where she was responsible for the supplemental new drug application (sNDA) registration filing of Gleevec(TM) in Ph+ adult acute lymphoblastic leukemia (ALL) and, as global clinical project leader, successfully brought the first FLT3 kinase inhibitor PKC412 (Midostaurin) to Phase 3 in acute myelogenous leukemia (AML). Earlier in her career at Novartis, Dr. Cohen was responsible for the early clinical development through Phase 1 and proof-of-concept at Novartis Oncology, and was an early proponent of the use of biomarkers to speed clinical decision making and optimize trial design. Dr. Cohen was also responsible for in-licensing activities for preclinical through Phases 1 to 3 oncology compounds and served as an in-house expert for pediatric oncology drug development. Prior to joining Novartis, Dr. Cohen held several academic positions in pediatric oncology at various institutions, including Cornell, UCLA, the National Cancer Institute, and Stanford University.

Dr. Cohen received her undergraduate degree from Barnard College, Columbia University and her medical degree from the Mount Sinai School of Medicine. She has received many awards and honors and has authored over 30 publications in the area of the molecular biology of pediatric and medical oncology, clinical development of targeted oncology therapeutics and the development of biomarkers for use in oncology drug development.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- a Hsp90 (heat shock protein 90) inhibitor and an epothilone. Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Tanespimycin (KOS-953) is be
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference
2. Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results
3. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
4. Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs
5. Kosans Board of Directors Appoints Helen S. Kim as Chief Executive Officer
6. Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference
7. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
8. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
9. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
10. Kosan Announces February 28, 2008 Conference Call and Webcast
11. Kosans Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2008)...es embedded with a telescope,promise to make it ea...do,other activities requiring sharper distance vis...scribe the advantages of these innovative glasses,...e May/June issue of,Journal of Biomedical Optics, ..."This new design has several advantages," says the...
(Date:7/24/2008)...ll/ -- American Oriental,Bioengineering, Inc. (NYS...,second quarter 2008 financial results on Monday, ...mpany will hold a conference call at 5:00 pm ET on...ter 2008 results. Listeners may,access the call by...rnational callers, access code: 41757592. A webcas...
(Date:7/24/2008).../- Poniard,Pharmaceuticals,...y focused,on oncology, today announced that it wil...second quarter results and provide a corporate upd...nt plan for picoplatin, the,Company,s lead product...ef,executive officer, Ronald A. Martell, president...
(Date:7/24/2008).../ -- Sagent Pharmaceuticals, Inc.,a privately-hel...d that it,has launched ceftazidime for injection, ...ntibiotic. Sagent will offer ceftazidime in 1,and ...vials. According to,IMS data, 2007 sales of inject...ately $45.7 million., "Sagent is proud to be prov...
Breaking Biology Technology:Telescope Embedded in Spectacle Lens Promises to Make Driving Easier for Visually Impaired 2Telescope Embedded in Spectacle Lens Promises to Make Driving Easier for Visually Impaired 3Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31 2Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP 2
... , New Advances in Scanner Design for Super..., , , The Affymetrix Gen...r continued evolution of the GeneChip platform a...g continued feature size reduction for higher reso...ay-based products. The Affymetrix GeneChip Scanner...
... Tunable Parameters of the Affymetrix Expressi...oduction , The Statistical Algorithms in ...set data to generate expression values (Signals an...ciated p-values for every transcript represented o...re used to generate transcript Detection and Chang...
...rometry Application Note , Melissa Chen, ...CA , Introduction , Rapid ide...ixtures is one of the key objectives for the use o...ionally, this approach has utilized 3-dimensional ...LCQ Deca XP Plus and the Finnigan ProteomeX. Recen...
...rometry Application Report , Key Words Se... Equine serum Acepromazine , Gargi Chou...SA , Wayne Skinner and Scott Stanley...oduction , Acepromazine is widely used a...r to better facilitate handling of these large mam...
Other Biology Technology:The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 2The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 3The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 4The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 5The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 6The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 7The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 8The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 9The Affymetrix GeneChip Scanner 3000, New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range 10Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 2Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 3Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 4Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 5Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 6Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 7Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 8Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 9Fine Tuning Your Data Analysis:, Tunable Parameters of the Affymetrix Expression Analysis Statistical Algorithms 10Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 2Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 3Complex Peptide Mixture Analysis on the Finnigan LTQ Linear Ion Trap Mass Spectrometer 4Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 2Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 3Determination of Acepromazine and its Major Metabolite in Equine Serum by LC-MS/MS using the Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer 4
(Date:7/23/2008)...enewable fuel source could generate enough electri...,s entire consumption needs and lead to a signific...according to US research published today, Thursday...ntal Research Letters . , The journal paper, ,Co...erting Manure to Biogas, has implications for all...
(Date:7/23/2008)...llectively spend about $1 billion annually could p...ic tons of carbon dioxide per year for the next 25...about that much money to put an end to a tenth of ...e top contributors to greenhouse gas emissions, re...rogram could have potential to reduce global carbo...
(Date:7/23/2008)...ernationally renowned scientists from 12 countries...lia and India to address ancient microscopic foss...ng together the world,s best scientists in the fie...iam Schopf, founder and director of the UCLA Insti...or the Study of Evolution and the Origin of Life (...
(Date:7/23/2008)...ards and Technology (NIST) have developed a techni... in protein-based pharmaceuticals. This first syst... scientists can be assured that their instruments ...aggregates, a major concern because of its impact ...ufacturing. , Proteins, a main constituent of ma...
Breaking Biology News(10 mins):Cow power could generate electricity for millions 2Paying to save tropical forests could be a way to reduce global carbon emissions 2Paying to save tropical forests could be a way to reduce global carbon emissions 3Paying to save tropical forests could be a way to reduce global carbon emissions 4UCLA 'world summit' to explore ancient life on Earth, and beyond 2NIST trumps the clumps: Making biologic drugs safer 2Safer easier system for remote explosive detection 4506 1Safer easier system for remote explosive detection 4506 2CamelBak 28R 29 CEO Statement on BPA and Plastic Re Usable Water Bottles 16442 1Haemacure Reports on its annual general and special meeting of shareholders 16438 1Haemacure Reports on its annual general and special meeting of shareholders 16438 2Haemacure Reports on its annual general and special meeting of shareholders 16438 3Haemacure Reports on its annual general and special meeting of shareholders 16438 4Aerobic Exercise Keeps You Young 16434 1Aerobic Exercise Keeps You Young 16434 2
...ure climate shows that the Sahel region, which exp... in the 1990s, could experience wetter monsoons fo...n Africa is projected to intensify further. Oceani...e gases appears to be a factor in these expected 2...Hurrell of the National Center for Atmospheric Res...
...d other causes of Sick Building Syndrome may impro... American Phytopathological Society (APS). , Sick...which building occupants experience health problem... issues typically associated with SBS range from a...problems involving exposure to toxins. , Mold is a...
...in plant science. , Scientists have known since 1...ey,ve known of its dramatic effects on plant growt... scientists know how it works. , In this week,s Na...rk Estelle, Nihal Dharmasiri and Sunethra Dharmasi...influences how and when plant cells grow and divid...
...mols suppress the growth of human cell lines repre...ary, pancreas, brain and blood, and reduce tumors ...addition, Enigmols did not show side effects at ef... at the Georgia Institute of Technology, Emory Uni...re funded by the National Cancer Institute. , "Ma...
Other Biology News:Africa to take it on chin again with climate change 2Africa to take it on chin again with climate change 3What's really making you sick? Plant pathologists offer the science behind Sick Building Syndrome 2At long last, scientists figure out how plants grow 2Researchers find promising cancer-fighting power of synthetic cell-signaling molecule 2Researchers find promising cancer-fighting power of synthetic cell-signaling molecule 3
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST).
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048
Mouse monoclonal antibody raised against a partial recombinant EOMES. NCBI Entrez Gene ID = EOMES
LTQ XL Linear Ion Trap from Thermo Scientific
Biology Products: